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users discontinue therapy within 1 year. Some nutraceuticals are prescribed as lipid-lowering sub-
stances, but doubts remain about their efﬁcacy and tolerability.
Objectives: We aimed to investigate the efﬁcacy and the safety of a nutraceutical combination consisting
mainly of 200 mg red yeast rice extract (equivalent to 3 mg monacolins), 500 mg berberine, and 10 mg
policosanols (MBP-NC) in patients with low-moderate risk hypercholesterolemia.
Methods: In this single centre, randomized, double-blind, placebo-controlled study 60 consecutive
outpatients (29 men and 31 women; age range ¼ 18–60 years), with newly diagnosed primary
hypercholesterolemia not previously treated, after a run-in period of 3 weeks on a stable hypolipidic
diet, were randomized to receive a pill of MBP-NC (n ¼ 30) or placebo (n ¼ 30) once a day after dinner,
in addition to the hypolipidic diet. The efﬁcacy and the tolerability of the proposed nutraceutical
treatment were fully assessed after 4, 12, and 24 weeks of treatment.
Results: In the MBP-NC group both total cholesterol and LDL-C already showed a signiﬁcant reduction at
Week 4 (–30.3% 7 33.9% and –29.4% 7 35.3%, respectively) that remained substantially unchanged at
Week 12 (–26.7% 7 33.1% and –25.6% 7 31.5%, respectively) and at Week 24 (–24.6% 7 32.1% and
–23.7% 7 32.6%, respectively). The between-groups differences were signiﬁcant at all time points for
both total cholesterol and LDL-C. There were no signiﬁcant changes in HDL-C, fasting glucose, and
triglyceride serum levels in either group. MBP-NC was also safe and well tolerated.
Conclusions: In patients with low- to moderate-risk hypercholesterolemia a nutraceutical combination in
association with a hypolipidic diet signiﬁcantly reduced total cholesterol and LDL-C levels and may favor
the reaching the recommended cholesterol targets. ClinicalTrials.gov identiﬁer: NCT02078167.
& 2014. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Many epidemiologic studies have shown that serum cholesterol
levels are strongly related to cardiovascular risk.1,2 Consequently
lowering cholesterol levels is a fundamental prognostic goal in the
primary and secondary prevention of cardiovascular events. The
3-hydroxy-3-methylglutaryl-coenzime A reductase inhibitors,
commonly known as statin drugs, are the drugs of ﬁrst choice to
lower serum cholesterol levels, especially in patients at high orInc. This is an open access article u
D, Department of Medicine,
inico Le Scotte, Viale Bracci 2,very-high risk of cardiovascular diseases, in view of their estab-
lished efﬁcacy in reducing cardiovascular mortality and morbidity
in both primary and secondary prevention.3,4 Statin drugs are
generally well tolerated and in controlled trials the adverse events
were similar in patients treated with statins and those treated
with placebo.4 However, in clinical practice, 10% to 15% of patients
are found to be intolerant to any statin drugs, even at low daily
doses and almost one-third of statin users discontinue therapy
within 1 year.5 Furthermore some other patients, especially in
primary prevention, refuse statin drugs because of the fear of
possible side effects. Some nutraceutical products may represent
an alternative treatment to be considered for the above-
mentioned cases, above all in patients with marginally high
hypercholesterolemia.4,6 Because the use of the full dose ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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nutraceuticals with different but synergic mechanisms of action at
lower and safer dosages could be preferable. In particular, in recent
years there has been growing interest in a nutraceutical combina-
tion containing monacolin (the biologically active component of
red yeast rice), berberine, and policosanols (MBP-NC). The
cholesterol-lowering effect of MBP-NC consumed in conjunction
with a standard Mediterranean healthy diet has been observed in a
large Italian study carried out by general practitioners7 in patients
intolerant to 41 statin,8 in patients with metabolic syndrome
or who are overweight,9,10 and in elderly patients with hyper-
cholesterolemia.11 Moreover, the MBP-NC mixture has been
reported to have some direct protective vascular effects, similar
to pharmacologic lipid-lowering agents, such as improvement in
endothelial dysfunction12 and improvement in aortic stiffness.13
Another recent study reported that a 2-month treatment with
MBP-NC improved insulin sensitivity in patients with metabolic
syndrome.14
Hitherto the cholesterol-lowering effect of MBP-NC has not
been evaluated in long-term double-blind, placebo-controlled
studies. The aim of our single-center, randomized, double-blind,
placebo-controlled study was to evaluate the efﬁcacy and the
safety of a 24-week treatment with a MBP-NC mixture in patients
with low-moderate risk hypercholesterolemia.Materials and Methods
Population
A cohort of 66 consecutive outpatients with newly diagnosed
primary hypercholesterolemia not previously treated who
applied to the lipid clinic of the Department of Internal Medi-
cine at the University of Siena, Italy, were considered for enrol-
ment in our study. The inclusion criteria were age between 18
and 60 years, body mass index between 18.5 and 29.9, serum
LDL-C 4150 mg/dL (3.88 mmol/L), and an estimated 10-year
cardiovascular risk o20% according to Framingham risk scoring.
The exclusion criteria were history of cardiovascular disease or
coronary risk equivalents; secondary hyperlipidemia caused by
diabetes mellitus, renal, liver, or thyroid diseases; alcohol con-
sumption 440 g/d; estimated 10-year cardiovascular risk
420% according to Framingham risk scoring; and muscular
diseases or abnormally elevated creatine phosphokinase (CPK)
levels or drug treatment with antiplatelet, anti-inﬂammatory, or
hypolipidemic agents, or hormone replacement therapy either
ongoing or any time during the previous 2 months. Instead, the
patients stable while taking antihypertensive treatment for at
least 3 months were included. All patients were instructed to
maintain their habitual physical activity during the study
period.
At the screening visit, all patients were instructed to follow a
hypolipidic diet (ie, low-cholesterol/low-saturated fat diet approx-
imately consisting of 55% carbohydrates, 20% proteins, and 25%
lipids) during a run-in period of 3 weeks, after which all patients
who met the inclusion criteria (29 men and 31 women), were
randomized to receive a pill of MBP-NC (n¼30) or placebo (n¼30)
once a day after dinner, in addition to the hypolipidic diet. The
placebo pills, identical in taste and appearance to the MBP-NC pills,
consisted of inactive compound. Randomization and blinding were
provided by Rottapharm Madaus SpA (Monza, Italy). The compo-
sition of the patented proprietary combination of nutraceuticals
investigated was 200 mg red yeast rice extract (equivalent to 3 mg
monacolins), 500 mg berberine, 10 mg policosanol, 0.2 mg folic
acid, 2 mg coenzyme Q10, and 0.5 mg asthaxantin (Armolipid Plus,
Rottapharm Madaus SpA).The study was conducted in accordance with the guidelines of
the Declaration of Helsinki, as revised in 2000 and 2008, and the
study protocol was approved by the Ethics Committee of the
University Hospital of Siena. Written informed consent was
obtained from each patient.Clinical and anthropometric evaluation
All patients underwent physical examination at baseline and
after 4, 12, and 24 weeks of treatment. All the determinations
were made at the lipid clinic at 9:00 AM, after an overnight fast of
12 hours. Height and weight were measured to the nearest 0.1 cm
and 0.1 kg, respectively. Body mass index was calculated as
weight in kilograms divided by height meters2. Brachial blood
pressure was measured by a physician with a mercury sphyg-
momanometer after patient had been seated for at least 10
minutes and the average of 3 measurements was considered for
the analysis. Waist circumference was also measured at each visit
midway between the lowest rib and the iliac crest using an
anthropometric tape.
In all patients, body composition (fat mass percentage, fat-free
mass, and fat-free mass to fat mass ratio) was assessed by
anthropometry and bioelectrical impedance analysis using a
single-frequency 50 kHz bioelectrical impedance analyzer (BIA
101 RJL, Akern Bioresearch, Florence, Italy). All bioelectrical impe-
dance analysis measurements were carried out by the same
operator according to the standard tetrapolar technique, with
patients in a supine position for at least 20 minutes. The electrodes
were placed on the dorsal surface of the right foot and ankle and
the right wrist and hand.Biochemical measurements
In all patients fasting venous blood samples were drawn at
baseline and after 4, 12, and 24 weeks to assess serum levels of
total cholesterol, triglycerides (TG), HDL-C, and LDL-C. All lipid
parameters were measured using a colorimetric method (Autoan-
alyzer, Menarini, Florence, Italy). In our institution the intra- and
interassay coefﬁcients of variation were, respectively, 1.8% and 3.8%
for total cholesterol, 2.0% and 3.0% for HDL-C, 1.7% and 2.9% for TG,
and 1.5% and 2.3% for LDL-C assessment. To monitor the safety of
the MBP-NC in all patients at the same time points serum levels of
glucose, uric acid, creatine phospho kinase (CPKw), gamma-
glutamiltranferase, and transaminases were also assessed. Toler-
ability was monitored by recording symptoms. Medication com-
pliance was assessed by counting the number of pills returned at
the clinic visits.Statistical analysis
All values were expressed as mean (SD). Clinical data and initial
values of the variables measured in the study groups were
compared using Student t test for unpaired data. The
Kolmogorov-Smirnov test was used to verify the normality of the
distribution of the outcome variables. For all parameters the
absolute changes over time for each patient were expressed as a
percentage of the baseline values. Paired t test and Wilcoxon
matched-pairs signed-rank test were used, where appropriate, to
compare the changes with baseline values. Two-way ANOVA for
repeated measures was used to compare the response of the study
variables to the 2 different treatments. All tests were 2-sided, and
P o 0.05 was considered statistically signiﬁcant. All tests were
performed using the SPSS statistical package for Windows version
16.0 (IBM-SPSS Inc, Armonk, New York).
Table I
Baseline characteristics of 60 patients with hypercholesterolemia randomized to
receive either a nutraceutical combination consisting mainly of 200 mg red yeast
rice extract (equivalent to 3 mg monacolins), 500 mg berberine, and 10 mg
policosanols (MBP-NC) or placebo.*
Characteristic MBP-NC Placebo P value
Men 15 14 —
Women 15 16 —
Age, y 46.4 (9.7) 46.4 (10.1) NS
Weight, kg 72.7 (12.7) 71.1 (12.9) NS
Body mass index 26.9 (4.9) 26.4 (4.1) NS
Waist circumference, cm 89.9 (10.9) 88.7 (10.9) NS
Glucose, mg/dL 92.5 (8.8) 94.4 (10.0) NS
Total cholesterol, mg/dL 238.4 (26.9) 248.1 (32.4) NS
HDL-C, mg/dL 53.1 (13.2) 55.7 (14.5) NS
LDL-C, mg/dL 162.0 (22.5) 165.8 (29.0) NS
Triglycerides, mg/dL 132.1 (55.2) 119.0 (50.4) NS
Uric acid, mg/dL 4.8 (1.5) 4.1 (1.6) NS
NS ¼ not signiﬁcant.
n Values are expressed as mean (SD), except sex, which is expressed as n.
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The demographic and clinical characteristics of the 60 patients
with hypercholesterolemia who were stable on the hypolipidic diet,
30 assigned to MBP-NC and 30 to placebo, are shown in Table I.
There were no signiﬁcant differences between the 2 groups in
baseline characteristics. Fifty-seven patients (28 in the MBP-NC
group and 29 in the placebo group) completed the 24-week study
period. One patient in the MBP-NC group withdrew from the study
for problems unrelated to the study drugs, whereas 2 patients (1 in
the MBP-NC group and 1 in the placebo group) withdrew for not
serious adverse events (Figure 1). All outcome variables were
distributed normally and there was no need for log transformation.
The percentage changes of lipid parameters with respect to baseline
in the 2 study groups are shown in Figure 1. In the MBP-NC group
both total cholesterol and LDL-C levels already showed a signiﬁcant
reduction at Week 4 (–30.3% 7 33.9% and –29.4% 7 35.3%,
respectively), which remained substantially unchanged at Week
12 (–26.7% 7 33.1% and –25.6% 7 31.5%, respectively) and at Week
24 (–24.6% 7 32.1% and –23.7% 7 32.6%, respectively), whereas
there were no signiﬁcant changes in the placebo arm. The between-
groups differences were signiﬁcant at all time points for both total
cholesterol and LDL-C (Figure 2). There were no signiﬁcant changesAssessed for eligibil
Randomized (n
MBP-NC + Hypolipidic diet (n=30)
Analyzed (n=28)
Lost follow-up (n=1)
Discontinued intervention
(constipation n=1)
Figure 1. Flow diagram of the study population. MBP-NC ¼ nutraceutical combination c
500 mg berberine, and 10 mg policosanols.in HDL-C and triglyceride serum levels in either group, although at
the end of the study period triglyceride levels were more reduced in
patients treated with MBP-NC than in those treated with placebo
(–22.9% 7 62.3% and –4.1% 7 35.3%, respectively) (Figure 1).
A 24-week treatment with either MBP-NC plus diet or placebo plus
diet showed similar effect on body weight (–2.8 kg and
–3.5 kg, respectively) and on waist circumference (–2.2 cm and
–2.6 cm, respectively) (Table II). No signiﬁcant differences were
observed between groups at all time points for anthropometric or
body composition parameters and for systolic and diastolic blood
pressure (Table II). MBP-NC treatment showed a tendency to reduce
serum levels of fasting glucose and of uric acid but without reaching
statistical signiﬁcance.
The mean values of hepatic parameters were unchanged at all
time points compared with baseline in both groups, and none of
the patients showed values higher than double the upper limit of
normal (ULN) range. Instead, CPK serum levels showed a slight
increase in MBP-NC group without reaching statistical signiﬁ-
cance (Table II). Four patients (3 in the MBP-NC group and 1 in
the placebo group) presented an increase in CPK levels higher
than 2 times the ULN during the study period, but at the end of
the study only a patient of the MBP-NC group presented CPK
levels higher than 2 times the ULN; however, none of these
patients complained of myalgia. Nine patients (15%) reported
symptoms. Symptom intensity was mild for all patients except for
a patient in the MBP-NC group who complained of moderate
constipation a Week 4 and was withdrawn from the study at
Week 12; a patient in the placebo group withdrew for abdominal
problems (Table III).Discussion
This is 1 of the ﬁrst randomized, placebo-controlled, double-
blind studies of adequate length (24 weeks) to evaluate the
safety and efﬁcacy of treatment with a low-dose combination of
red yeast rice, berberine, and policosanols in patients with mild-
to-moderate hypercholesterolemia. Our study conﬁrms that a
combined therapy of low-dosage nutraceuticals with different
mechanisms of action may contribute to reducing cholesterol
levels more than the different components of the MBP-NC used
individually. In a meta-analysis of 93 trials red yeast rice prepara-
tions showed short-term beneﬁcial effects on LDL-C levels.15
Moreover, in a large Chinese population with previous myocardiality (n=66)
=60)
Excluded (n=6)
Not meeting inclusion criteria (n=5)
Declined to participate (n=1)
Placebo + Hypolipidic diet (n=30)
Discontinued intervention
(Abdominal pain n=1)
Analyzed (n=29)
onsisting mainly of 200 mg red yeast rice extract (equivalent to 3 mg monacolins),
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Figure 2. Percentage changes from baseline in (A) total cholesterol, (B) LDL-C, (C) HDL-C, and (D) triglycerides in patients with hypercholesterolemia treated for 24 weeks
with a nutraceutical combination consisting mainly of 200 mg red yeast rice extract (equivalent to 3 mg monacolins), 500 mg berberine, and 10 mg policosanols (n ¼30) or
placebo (n¼30).
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signiﬁcantly reduced not only LDL-C by about 20% but also the risk
of future major coronary events.16 The positive effect of red yeast
rice on cholesterol levels is attributed to an inhibition of
3-hydroxy-3-methylglutaryl-coenzime A reductase due to its
monacolin-K content, which is chemically identical to lovastatin.17
Moreover, a recent study18 carried out in patients intolerant to
statin drugs reported that red yeast rice preparations induced a
dose-dependent decrease of LDL-C levels without serious adverse
effects. However in all these studies red yeast rice preparations
were used in daily doses, ranging from 1.2 to 4.8 g—much higher
than that present in the nutraceutical pills administered in our
study—accounting for some reports of myopathy in patients
treated with high doses of red yeast rice. The cholesterol-Table II
Anthropometric, clinical, and biochemical parameters of 60 patients with hypercholester
of 200 mg red yeast rice extract (equivalent to 3 mg monacolins), 500 mg berberine, an
Parameter MBP-NC
Baseline 4 weeks 12 weeks 2
Weight, kg 72.7 (12.7) 71.8 (12.5) 70.5 (12.6) 6
Waist circumference, cm 89.9 (10.9) 89.1 (11.0) 87.5 (10.0)
Lean mass/fat mass 2.7 (1.3) 2.9 (1.3) 3.1 (1.5)
Fat percentage 27.6 (7.9) 26.7 (7.9) 26.6 (8.7) 2
Glucose, mg/dlL 92.5 (8.8) 90.4 (9.7) 92.1 (10.1) 9
SBP, mm Hg 120.1 (11.1) 117.1 (12.5) 115.4 (11.5) 1
DBP, mm Hg 77.2 (7.0) 74.8 (8.8) 77.3 (9.3) 7
Uric acid, mg/dL 4.8 (1.5) 4.4 (1.3) 4.4 (1.3)
CPK, mU/mL 111.3 (38.0) 117.8 (72.3) 125.2 (70.5) 14
ALT, IU/L 20.5 (5.3) 21.2 (5.4) 21.0 (6.0) 1
AST, IU/L 23.0 (10.8) 23.6 (11.2) 23.9 (13.0) 1
ɣGT, IU/L 24.0 (13.7) 27.8 (18.7) 30.3 (21.5) 2
ALT ¼ alanine aminotrasferase; AST ¼ aspartate aminotrasferase; CPK ¼ creatine pho
SBP ¼ systolic blood pressure.
n Values are expressed as mean (SD).lowering efﬁcacy of policosanols is still controversial. Indeed, some
Cuban studies reported that policosanols were effective at pro-
ducing signiﬁcant reductions in cholesterol levels and also some
antiatherogenic effects. However, more recent randomized con-
trolled trials in white patients with hyperlipidemia did not ﬁnd
any lipid-lowering effect of policosanols.19 Berberine, a natural
plant extract from Berberis aristata bark, has been reported as able
to reduce serum cholesterol levels by increasing LDL-C receptors
on the surface of liver cells and in inhibiting triglycerides biosyn-
thesis.10,20,21 Moreover, a recent study has reported that in Asian
patients with type 2 diabetes mellitus, berberine ameliorated
insulin sensitivity and improved the management of diabetes.22
However the high dosages employed (1.5 g/d) were often asso-
ciated with gastrointestinal disorders.22 Therefore, berberine andolemia randomized to receive either a nutraceutical combination consisting mainly
d 10 mg policosanols (MBP-NC) or placebo.*
Placebo
4 weeks Baseline 4 weeks 12 weeks 24 weeks
9.9 (13.0) 71.0 (12.9) 69.8 (12.9) 69.6 (13.0) 67.5 (12.6)
87.1 (9.1) 88.6 (10.9) 87.0 (9.8) 87.8 (10.4) 86.0 (9.3)
3.1 (1.4) 2.9 (1.5) 2.9 (1.3) 3.0 (1.2) 3.0 (1.4)
7.2 (9.2) 27.0 (7.3) 26.9 (6.3) 26.2 (6.1) 26.9 (6.5)
0.7 (12.9) 92.4 (10.0) 94.6 (9.0) 92.5 (10.0) 97.4 (12.8)
17.1 (13.0) 119.1 (19.7) 121.2 (13.4) 117.5 (16.9) 119.0 (18.4)
6.2 (6.8) 75.2 (10.0) 78.2 (7.7) 76.5 (8.6) 75.3 (10.3)
4.1 (1.3) 4.1 (1.2) 4.1 (1.5) 3.9 (1.2) 3.7 (1.4)
0.4 (83.0) 107.6 (41.8) 118.7 (67.1) 110.3 (44.4) 96.8 (39.6)
9.9 (4.1) 20.3 (6.0) 20.5 (5.1) 20.0 (6.1) 18.8 (4.7)
9.9 (8.8) 20.6 (12.2) 21.2 (11.2) 21.3 (12.1) 21.2 (10.4)
7.5 (15.4) 21.1 (15.4) 21.5 (16.3) 21.7 (15.6) 24.1 (22.6)
sphate kinase; DBP ¼ diastolic blood pressure; ɣGT ¼ ɣ-glutamyltranspeptidase;
Table III
Number of patients with symptoms or events judged as probably, possibly, or
certainly related to the treatment with either a nutraceutical combination consist-
ing mainly of 200 mg red yeast rice extract (equivalent to 3 mg monacolins), 500
mg berberine, and 10 mg policosanols (MBP-NC) or placebo.*
Symptom/event MBP-NC group (n ¼ 30) Placebo group (n ¼ 30)
Constipation 2 1
Muscle pain 0 1
Dizziness 1 0
Dyspepsia 1 0
Meteorism/bloating 1 1
Diarrhea 0 1
n Symptoms intensity for all patients of both groups was mild except for
1 patient in the MBP-NC group who presented moderate constipation.
S. Gonnelli et al. / Current Therapeutic Research 77 (2015) 1–6 5red yeast rice may be expected to have a synergistic effect on
inhibition of hepatic lipids synthesis. The results of our study, in
terms of total cholesterol and LDL-C reduction, are consistent with
other randomized, placebo-controlled studies in which MBP-NC
was administered for 4,23 6,12 8,13 or 5611 weeks.
In agreement with some studies,11,13,14,24 but in disagreement
with others7,10 we failed to ﬁnd any signiﬁcant effect of MBP-NC
on both TG and HDL-C levels. This ﬁnding might be due to the
relatively low dosages of berberine and red yeast rice; moreover,
the normal baseline levels of TG and HDL-C might have contrib-
uted to further lessen the effect of MBP-NC treatment on these
lipid variables. In disagreement with other studies,10,14 our pop-
ulation receiving MBP-NC did not show any signiﬁcant changes in
glucose serum levels. This ﬁnding might be due to the relatively
low dosages of berberine and to the fact that in the present study
patients with obesity or prediabetes were excluded. The afore-
mentioned ﬁndings have stimulated an interest in deﬁning the
clinical conditions in which nutraceuticals could be recommended.
According to the more recent guidelines of the European Society of
Cardiology, the best indication may be represented by patients
with hypercholesterolemia and low-to-moderate cardiovascular
risk.4 In these patients the taking nutraceuticals in combination
with a hypolipidic diet may facilitate reaching target cholesterol
levels. Another indication for MBP-NC might be for those patients
who would perhaps need treatment with statins but were pre-
viously found to be intolerant to statins or refused treatment with
these drugs. In fact, recently Pisciotta et al24 reported that in
patients with primary hypercholesterolemia 6-month treatment
with MBP-NC was more effective than 10 mg/d ezetimibe in
lowering LDL-C and was well tolerated.
A key point for treatment with nutraceuticals is their safety and
tolerability. In particular, European Society of Cardiology guide-
lines have stated that long-term data regarding tolerability of red
yeast rice are scarce.4 Our study has conﬁrmed the good toler-
ability of MBP-NC; in fact, the patients treated with MBP-NC
presented a very low incidence of adverse reactions that were
mild, except 1 patient who was withdrawn from the study because
of moderate constipation.
Our study has some limitations: ﬁrst, the relatively low sample
size; second, a 24-week study period, although it was longer with
respect to the majority of previous studies, might be inadequate to
evaluate the long-term efﬁcacy of MBP-NC. Finally, we tested the
combination mixture effects but not the effects of the single
components.Conclusions
In patients with low-to-moderate-risk hypercholesterolemia
the MBP-NC in association with a hypolipidic diet reduces total
cholesterol and LDL-C and may favor reaching the recommendedcholesterol targets. Further studies are warranted to investigate
whether long-term treatment with this kind of nutraceutical
combination may prevent cardiovascular complications.Acknowledgment
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